2-Methylbutyryl-CoA Dehydrogenase Deficiency

1. Disease Information

Overview

2-Methylbutyryl-CoA dehydrogenase deficiency is a rare organic acidemia classified as an inborn error of branched-chain amino acid metabolism. It was first described in 2002–2003 by Gibson, Matern and colleagues as "a recently described autosomal recessive disorder of L-isoleucine metabolism" (PMID: 12837870). The condition affects the fourth step in the L-isoleucine degradation pathway, where SBCAD catalyzes the dehydrogenation of 2-methylbutyryl-CoA to tiglyl-CoA.

Key Identifiers

Synonyms and Alternative Names

• Short/branched-chain acyl-CoA dehydrogenase deficiency (SBCADD)
• 2-MBAD deficiency
• 2-Methylbutyrylglycinuria (2-MBG)
• SBCAD deficiency
• 2-MBCD deficiency

Information Sources

Information is derived from both aggregated disease-level resources (OMIM, Orphanet, GeneReviews) and individual patient reports/case series in the primary literature. The largest systematic review encompasses 162 reported patients (PMID: 30730842). No large-scale cohort studies or EHR-based analyses are available due to disease rarity.

2. Etiology

Disease Causal Factors

2-MBDD is exclusively genetic in origin. It is caused by biallelic (homozygous or compound heterozygous) loss-of-function mutations in the ACADSB gene, which encodes the short/branched-chain acyl-CoA dehydrogenase enzyme. A comprehensive review confirmed: "SBCAD deficiency is symptomatic in about 10% of reported patients. Clinical onset occurs in newborns or later in life with seizures, developmental delay, hypotonia, and failure to thrive" (PMID: 30730842).

Risk Factors

Genetic Risk Factors

• Biallelic ACADSB mutations: Required for disease manifestation (autosomal recessive)
• Hmong ancestry: The c.1165A>G founder mutation has extremely high carrier frequency in the Hmong population. In Wisconsin, "Of the remaining 92 confirmed SBCADD cases, 90 were of Hmong descent" (PMID: 23712021)
• Somali/Eritrean ancestry: The c.303+3A>G splice variant is "relatively prevalent in this population" (PMID: 17883863)
• Consanguinity: Increases risk for homozygous pathogenic variants, as shown in Iranian cases (PMID: 41527137, PMID: 36604934)

Environmental Risk Factors

• Metabolic stress: Illness, fever, fasting, and catabolic states may trigger metabolic decompensation in susceptible individuals
• Valproic acid exposure: Valproyl-CoA competitively inhibits SBCAD activity (Ki = 249 ± 29 μM) (PMID: 21430231), potentially worsening the metabolic block
• Protein overload: High isoleucine intake increases flux through the impaired catabolic pathway

Protective Factors

Genetic Protective Factors

• Residual enzyme activity from milder missense variants may explain asymptomatic phenotype in many patients
• "The relatively high prevalence of ACADSB gene mutations in control subjects suggests that MBD deficiency may be more common than previously thought but is not detected because of its usually benign nature" (PMID: 17945527)

Environmental Protective Factors

• Early identification via newborn screening: Allows presymptomatic intervention
• Avoidance of metabolic stress: Fasting avoidance and illness management
• L-carnitine supplementation: May help maintain metabolic homeostasis
• R-pathway shunting: An alternative metabolic route (R-pathway of isoleucine oxidation) may act as "a safety valve for overflow of accumulating S-pathway metabolites and thereby mitigate the severity of SBCADD" (PMID: 15615815)

Gene–Environment Interactions

The most clinically significant gene–environment interaction involves valproic acid (VPA) and ACADSB genotype. Since "valproyl-CoA did inhibit SBCAD activity by a purely competitive mechanism with a K(i) of 249 ± 29 μM" (PMID: 21430231), individuals with reduced SBCAD enzyme activity are particularly vulnerable to valproic acid-induced metabolic crisis. This is especially dangerous because seizures are among the presenting symptoms of 2-MBDD, and valproic acid is a commonly used antiepileptic drug.

3. Phenotypes

Clinical Spectrum

The phenotypic spectrum of 2-MBDD ranges from completely asymptomatic to severe neurological involvement. A review of 162 patients established that approximately 90% remain asymptomatic (PMID: 30730842).

Phenotype Details

Quality of Life Impact

For the vast majority (~90%) of identified individuals, quality of life is unaffected as they remain asymptomatic. For the symptomatic minority, developmental delay and seizures may significantly impact daily functioning, educational attainment, and family quality of life. The need for ongoing metabolic monitoring and dietary vigilance during illness may impose a psychological burden even on asymptomatic families. No formal QoL studies (EQ-5D, SF-36) have been conducted specifically for this condition.

4. Genetic/Molecular Information

Causal Gene

The original cDNA was cloned and characterized by Rozen et al. (1994): "The cDNA has significant sequence similarity to other members of the acyl-CoA dehydrogenase family, with the greatest homology (38%) to the short chain acyl-CoA dehydrogenase" (PMID: 7698750).

Protein Characteristics

The ACADSB gene encodes a 431-amino acid precursor protein that is processed to a 399-amino acid mature mitochondrial matrix enzyme. It is an FAD-dependent flavoenzyme that forms a homotetramer. The enzyme catalyzes the α,β-dehydrogenation of short/branched-chain acyl-CoA substrates, with activity on: - (S)-2-methylbutyryl-CoA (primary physiological substrate) - Isobutyryl-CoA - 2-Methylhexanoyl-CoA - Butyryl-CoA - Hexanoyl-CoA

The enzyme uses electron transfer flavoprotein (ETF) as its physiologic electron acceptor, feeding electrons into the mitochondrial respiratory chain via ETF:ubiquinone oxidoreductase (ETFDH).

Pathogenic Variants

All known pathogenic variants are germline in origin. Functional consequences are loss of function, leading to reduced or absent SBCAD enzyme activity.

Modifier Genes

No specific modifier genes have been identified for 2-MBDD. However, the variable expressivity (90% asymptomatic vs. 10% symptomatic) suggests the involvement of genetic modifiers. Variation in ETFA/ETFB/ETFDH (electron transfer flavoprotein pathway) or genes governing the R-pathway of isoleucine oxidation could potentially affect disease severity.

Epigenetic and Chromosomal Information

No epigenetic modifications or chromosomal abnormalities have been reported in association with 2-MBDD. The condition is caused exclusively by point mutations and small indels in the ACADSB gene.

5. Environmental Information

Environmental Factors

• Metabolic stressors: Febrile illness, prolonged fasting, surgical stress, and trauma can precipitate metabolic decompensation by increasing isoleucine catabolism
• Valproic acid: Valproyl-CoA competitively inhibits SBCAD (Ki = 249 ± 29 μM); this drug is strictly contraindicated (PMID: 21430231)
• Riboflavin deficiency: Since SBCAD is FAD-dependent, severe riboflavin deficiency could theoretically worsen the enzymatic defect, though this has not been specifically studied in 2-MBDD. Riboflavin deficiency is known to impair fatty acid β-oxidation generally (PMID: 29185933)

Lifestyle Factors

• Dietary protein intake: High-protein diets increase isoleucine load, potentially exacerbating metabolite accumulation
• Fasting: Increases catabolism of endogenous branched-chain amino acids
• Breastfeeding: Generally well-tolerated and recommended with appropriate monitoring (PMID: 41527137)

Infectious Agents

Not applicable. 2-MBDD is not caused by infectious agents. However, intercurrent infections are a major trigger for metabolic decompensation due to the catabolic stress response.

6. Mechanism / Pathophysiology

Molecular Pathway

2-MBDD affects the isoleucine degradation pathway (KEGG pathway: hsa00280 — Valine, leucine, and isoleucine degradation). The specific enzymatic step impaired is:

L-Isoleucine
    ↓ (BCAT — transamination)
3-Methyl-2-oxopentanoic acid (α-keto-β-methylvaleric acid)
    ↓ (BCKDH complex — oxidative decarboxylation)
2-Methylbutyryl-CoA (S-2-methylbutyryl-CoA)
    ↓ ✖ SBCAD (ACADSB) — BLOCKED IN 2-MBDD ✖
Tiglyl-CoA
    ↓ (Crotonase)
2-Methyl-3-hydroxybutyryl-CoA
    ↓ (HSD17B10/HADH2)
2-Methylacetoacetyl-CoA
    ↓ (β-Ketothiolase/T2)
Propionyl-CoA + Acetyl-CoA → TCA cycle

Metabolite Accumulation

The enzymatic block leads to accumulation of: - 2-Methylbutyryl-CoA → conjugated with glycine to form 2-methylbutyrylglycine (2-MBG) - 2-Methylbutyryl-CoA → conjugated with carnitine to form 2-methylbutyrylcarnitine (C5) - 2-Ethylhydracrylic acid (2-EHA) — formed via the alternative R-pathway of isoleucine oxidation (PMID: 15615815)

Oxidative Stress Mechanism

The key pathophysiological mechanism linking metabolite accumulation to neurological damage is oxidative stress in brain tissue. An in vitro study using rat cerebral cortex and C6 glioma cells demonstrated:

"2MBG increased thiobarbituric acid-reactive substances (TBA-RS), indicating an increase of lipid oxidation. 2MBG induced sulfhydryl oxidation in cortical supernatants and decreased glutathione (GSH) in these brain preparations, as well as in C6 cells, indicating a reduction of nonenzymatic brain antioxidant defenses." (PMID: 22967964)

Key findings from this study: - 2-Methylbutyrylglycine (2-MBG) induced lipid peroxidation (increased TBA-RS) - 2-MBG caused sulfhydryl oxidation and decreased glutathione (GSH) - Effects were prevented by free radical scavengers, implicating reactive oxygen species (ROS) - The parent acid 2-methylbutyric acid did not alter these parameters, identifying 2-MBG as the neurotoxic species - No protein carbonyl formation or cell death was observed at tested concentrations

Causal Chain: From Genetic Defect to Clinical Manifestation

ACADSB mutations (loss of function)
    → Impaired 2-methylbutyryl-CoA dehydrogenation
→ Accumulation of 2-methylbutyryl-CoA and conjugates
    → 2-MBG accumulates in tissues including brain
→ ROS generation → Lipid peroxidation
→ GSH depletion → Reduced antioxidant defense
    → Neuronal oxidative damage
        → Seizures, developmental delay, hypotonia

R-Pathway Safety Valve

A potentially protective mechanism involves shunting through the R-pathway of isoleucine oxidation. Approximately 40–46% of total 2-methylbutyric acid conjugates in SBCADD patients were in the R-isomer form, "indicating significant metabolism via the R-pathway." The observation of 2-ethylhydracrylic aciduria in SBCADD "implies that a different or alternative enzyme serves this function" and "Increased flux through the R-pathway may act as a safety valve for overflow of accumulating S-pathway metabolites" (PMID: 15615815).

Protein Dysfunction

SBCAD protein dysfunction results from: - Enzyme inactivation: Missense mutations leading to loss of catalytic activity - Protein instability: Mutations causing misfolding and degradation - Splice defects: The Hmong founder mutation causes exon 10 skipping, producing a truncated non-functional protein

Relevant GO Terms

Cell Types Involved

Molecular Profiling

No transcriptomic, proteomic, metabolomic, or lipidomic profiling studies have been specifically conducted in 2-MBDD patients or cells. The metabolomic signature is characterized by elevated 2-methylbutyrylcarnitine (C5), 2-methylbutyrylglycine, and 2-ethylhydracrylic acid. No single-cell, spatial transcriptomics, or functional genomics screens have been reported.

7. Anatomical Structures Affected

Organ Level

Body systems involved: Nervous system (primary), musculoskeletal system, metabolic system.

Tissue and Cell Level

• Nervous tissue (UBERON:0003714): Neurons and glia affected by oxidative stress from accumulating metabolites
• Glial cells (CL:0000125): C6 glioma cells showed GSH depletion in response to 2MBG (PMID: 22967964)
• Neurons (CL:0000540): Likely targets of neurotoxicity

Subcellular Level

• Mitochondria (GO:0005739): Primary site of metabolic block; SBCAD is a mitochondrial matrix enzyme
• Mitochondrial matrix (GO:0005759): Specific compartment where SBCAD functions
• Cell membrane lipids: Target of lipid peroxidation by 2MBG

Localization

• Brain (UBERON:0000955): Cerebral cortex particularly affected based on experimental evidence
• Bilateral: Neurological manifestations are typically bilateral and symmetric
• No specific lateralization reported

8. Temporal Development

Onset

• Typical age of onset: Variable
• Biochemical abnormalities: Detectable at birth (neonatal period) via newborn screening
• Clinical symptoms (when present): Neonatal period to early childhood
• Some patients may remain asymptomatic indefinitely into adulthood
• Onset pattern: Insidious or episodic (triggered by metabolic stress)

Progression

• Disease stages: Not formally staged
• Progression rate: Variable; most patients show no progression (remain asymptomatic)
• Disease course pattern:
• Majority: Stable, asymptomatic (lifelong biochemical abnormality without clinical disease)
• Symptomatic minority: May be episodic (triggered by metabolic stress) or show progressive developmental delay
• Disease duration: Chronic, lifelong metabolic defect

Critical Periods

• Neonatal period: Window of vulnerability for acute metabolic decompensation
• Early brain development: Vulnerable period for neurotoxicity from accumulating metabolites
• Any catabolic state: Illness, surgery, fasting at any age

9. Inheritance and Population

Inheritance Pattern

• Inheritance: Autosomal recessive (AR) (HP:0000007)
• Penetrance: Incomplete; approximately 10% of individuals with biallelic mutations develop symptoms
• Expressivity: Highly variable, even within families with the same genotype
• Genetic anticipation: Not described
• Germline mosaicism: Not reported

Epidemiology

Founder Effects

Two major founder mutations have been identified:

1. Hmong population — c.1165A>G: This mutation causes exon 10 skipping. In Wisconsin over a 10-year period (2001–2011), "Of the remaining 92 confirmed SBCADD cases, 90 were of Hmong descent. Mutation analysis was completed on an anonymous, random sample of newborn screening cards (n=1139) from Hmong infants" with 15 carriers identified (PMID: 23712021). "While the first reported patients had severe disease, most of the affected Hmong have remained asymptomatic" (PMID: 20547083).

2. Somali/Eritrean population — c.303+3A>G: "This mutation was also found in two previously reported cases with SBCADD, both originating from Somalia and Eritrea, indicating that it is relatively prevalent in this population" (PMID: 17883863).

Geographic Distribution of Specific Variants

• c.1165A>G: Southeast Asia (Hmong communities in Laos, Vietnam, Thailand, southern China, and diaspora in US/France/Australia)
• c.303+3A>G: East Africa (Somalia, Eritrea)
• c.275C>G, c.655G>A: Chinese NBS populations
• c.907G>C: Iran (PMID: 41527137)

Population Demographics

• Sex ratio: Expected 1:1 (autosomal recessive); no sex predilection reported
• Consanguinity: Increases risk, particularly relevant in Middle Eastern and North African populations (PMID: 36604934)
• Carrier frequency (Hmong): ~1.3% (15/1,139 screened newborns) (PMID: 23712021)

10. Diagnostics

Newborn Screening (Primary Detection Method)

2-MBDD is primarily detected through expanded newborn screening (NBS) using tandem mass spectrometry (MS/MS): - Primary marker: Elevated C5-acylcarnitine (isovalerylcarnitine/2-methylbutyrylcarnitine) in dried blood spots - Typical screening values: C5 between 0.6–2.1 μmol/L in affected patients (normal <0.5 μmol/L) (PMID: 36709932) - Challenge: C5-acylcarnitine is isobaric — it cannot distinguish between isovalerylcarnitine (elevated in isovaleric acidemia) and 2-methylbutyrylcarnitine (elevated in 2-MBDD) - MAXO term: MAXO:0000127 (newborn screening)

Second-Tier Testing

Second-tier LC-MS/MS methods can differentiate C5-acylcarnitine isoforms: "Data from the analysis of short-chain acylcarnitine and acylglycine were useful for differential diagnosis in cases positive for... C5-acylcarnitine" (PMID: 34287228). UPLC-MS/MS analysis can separate isovalerylcarnitine, 2-methylbutyrylcarnitine, and pivaloylcarnitine (PMID: 23499962).

Confirmatory Testing

Differential Diagnosis

Genetic Testing

• Whole exome sequencing (WES): Effective for diagnosis, used in the first Iranian case (PMID: 41527137)
• Single gene testing: ACADSB Sanger sequencing (11 exons)
• Targeted mutation analysis: For known founder mutations in Hmong and Somali/Eritrean populations
• Gene panels: Organic acidemia/inborn errors of metabolism panels that include ACADSB

Screening

• Newborn screening: Part of expanded NBS panels in many countries using MS/MS
• Cascade screening: Recommended for siblings of affected individuals
• Carrier screening: Available for known founder mutations
• Prenatal diagnosis: Possible via molecular analysis of ACADSB mutations on CVS or amniocentesis

11. Outcome / Prognosis

Overall Prognosis

The prognosis for 2-MBDD is generally excellent. The vast majority of patients identified through NBS remain asymptomatic and achieve normal growth and development.

• In one Chinese NBS cohort of 12 patients followed 18 days to 55 months: "Only one patient had mental retardation, with the remainders having normal physical and mental development" (PMID: 36709932)
• In the Italian cohort: "As all patients were asymptomatic, no association between biochemical parameters and clinical phenotype could be investigated" (PMID: 36147814)
• "MBD deficiency may be a harmless metabolic variant although significant impairment of valproic acid metabolism cannot be excluded" (PMID: 17945527)

Survival and Mortality

• Life expectancy: Likely normal for the vast majority of patients
• Mortality: No disease-specific mortality has been reported in NBS-detected cohorts
• Disease-specific mortality: Extremely rare; no deaths directly attributed to 2-MBDD in screened populations

Complications

• Metabolic crisis: Risk during catabolic stress (illness, fasting, surgery)
• Neurological sequelae: Developmental delay, intellectual disability in ~10% of reported cases
• Pharmacogenomic risk: Valproic acid toxicity in undiagnosed individuals

Prognostic Factors

• Genotype: Severity of ACADSB mutations (null vs. partial loss of function) may influence risk
• Early detection: NBS-detected patients managed proactively have excellent outcomes
• Avoidance of triggers: Fasting, catabolic stress, valproic acid

12. Treatment

Pharmacotherapy

L-Carnitine Supplementation (MAXO:0001298)

• Rationale: Buffers accumulating acyl-CoA intermediates; prevents secondary carnitine deficiency
• Typical dose: 50–100 mg/kg/day (standard for organic acidemias)
• Evidence: An Italian study found "relatively stable serum C5 values observed during L-carnitine supplementation together with C5 increase occurring upon L-carnitine discontinuation/intercurrent illness may support the value of serum C5 as a monitoring biomarker and the benefit of this treatment in SBCADD patients" (PMID: 36147814)

Drug Avoidance

• Valproic acid is strictly contraindicated: "valproyl-CoA did inhibit SBCAD activity by a purely competitive mechanism with a K(i) of 249 ± 29 μM" (PMID: 21430231)
• Alternative antiepileptic drugs should be selected for seizure management

Dietary Management (MAXO:0000527)

• Protein restriction: Mild to moderate restriction of protein/isoleucine intake recommended in some symptomatic cases
• Breastfeeding: Generally continued with monitoring; in the first Iranian case "The infant was managed with a carnitine-supplemented diet and continued breastfeeding. Regular follow-ups demonstrated normal growth, neurodevelopmental milestones, and biochemical parameters" (PMID: 41527137)
• Fasting avoidance: Important during illness and catabolic states

Emergency Management

• Sick-day protocols: During intercurrent illness, provide increased caloric intake (glucose infusion if needed), avoid prolonged fasting
• Emergency letter: Patients should carry a metabolic emergency letter

Supportive and Rehabilitative

• Neurodevelopmental follow-up: Recommended for all identified patients
• Regular biochemical monitoring: C5-acylcarnitine levels, urine organic acids
• Developmental services: For symptomatic patients with developmental delay

Investigational/Experimental Treatments

• Antioxidant therapy: Given the oxidative stress mechanism (PMID: 22967964), antioxidants are a rational therapeutic target, but no clinical trials exist. "Prospective studies are needed to test the effectiveness of adjunct therapies such as antioxidants... in addition to specialized diets" (PMID: 21290185)
• Growth hormone: One study on organic acidemia patients (including one with an isoleucine metabolism defect) showed increased linear growth and nitrogen retention (PMID: 7993663), but this has not been specifically studied in 2-MBDD
• Riboflavin supplementation: As SBCAD is FAD-dependent, riboflavin responsiveness should be assessed in patients with missense mutations, though this has not been systematically studied
• Gene therapy: No gene therapy trials are currently registered for 2-MBDD
• No clinical trials specifically for 2-MBDD are registered on ClinicalTrials.gov

Treatment Strategy

Given the uncertain clinical significance in most patients, "With the individual life-time risk and degree of severity being unknown in asymptomatic individuals with MBDD or IBDD, instructions regarding risks for metabolic stress and fasting avoidance along with clinical monitoring are reasonable interventions at the current time" (PMID: 21290185).

13. Prevention

Primary Prevention

• Genetic counseling (MAXO:0000079): For families with known ACADSB mutations; recurrence risk 25% for each subsequent pregnancy of carrier parents
• Carrier screening: Targeted screening in high-risk populations (Hmong, Somali/Eritrean)
• Prenatal genetic diagnosis: Available for families with known pathogenic variants
• Preimplantation genetic diagnosis (PGD): Technically feasible for families undergoing IVF

Secondary Prevention (Early Detection)

• Newborn screening (MAXO:0000127): MS/MS-based expanded newborn screening detects elevated C5-acylcarnitine in dried blood spots. This is the primary method of case ascertainment.
• Cascade screening: Testing of siblings of identified patients
• Metabolic screening in high-risk populations: Particularly Hmong and Somali/Eritrean communities

Tertiary Prevention

• Metabolic monitoring: Regular follow-up with metabolic specialist
• Sick-day protocols: Prevent metabolic crises during illness
• Valproic acid avoidance: Critical pharmacogenomic counseling for all patients and families
• Dietary management: Avoid excessive protein/isoleucine loading
• L-carnitine supplementation: May prevent secondary carnitine deficiency

Public Health Considerations

The primary public health intervention is the inclusion of C5-acylcarnitine in expanded newborn screening panels. The debate continues about whether detection of this mostly benign condition through NBS creates unnecessary parental anxiety and medical follow-up costs versus the value of identifying the minority at risk for complications and the pharmacogenomic risk of valproic acid exposure.

14. Other Species / Natural Disease

Naturally Occurring Disease

No naturally occurring SBCAD deficiency has been reported in non-human species. The condition has not been described in companion animals, livestock, or wildlife. No entry for SBCADD exists in the Online Mendelian Inheritance in Animals (OMIA) database.

Orthologous Genes

Comparative Biology

• The isoleucine catabolic pathway is highly conserved across vertebrates
• Rat cerebral cortex tissue has been used as an experimental system to study the pathophysiology of accumulating metabolites (PMID: 22967964)
• Species differences in BCAA catabolism exist between mice and humans, which should be considered when developing animal models (PMID: 32451238)

Transmission

Not applicable. 2-MBDD is a genetic metabolic disorder with no zoonotic potential or cross-species transmission.

15. Model Organisms

Available Models

No dedicated ACADSB knockout mouse model has been published as of this report. This represents a significant gap in the field.

In Vitro Models

Related Animal Models in the ACAD Family

The closely related ACAD9 gene has been modeled in mice: - "Homozygous total body knock out appeared to be lethal as no ACAD9 animals were obtained" - "Cardiac-specific ACAD9 deficient animals had severe neonatal cardiomyopathy and died by 17 days of age" (PMID: 34556413)

While ACAD9 deficiency is a distinct disorder (affecting complex I assembly rather than isoleucine catabolism), these models provide insights into the broader acyl-CoA dehydrogenase family.

Model Limitations

• No whole-organism models available for studying systemic effects
• In vitro oxidative stress studies used potentially supraphysiological metabolite concentrations
• Rat models may not fully recapitulate human isoleucine metabolism
• The variable penetrance seen in humans cannot be studied in current in vitro models
• The E. coli expression system only addresses enzyme function, not disease pathophysiology

Research Applications Needed

Development of an Acadsb knockout mouse would enable study of: - Long-term neurological outcomes - Metabolic decompensation triggers - Valproic acid interaction in vivo - Therapeutic interventions (carnitine, antioxidants, riboflavin) - Genotype-phenotype correlations

Key Findings Summary

1. 2-MBDD is a rare autosomal recessive organic acidemia caused by ACADSB gene mutations, affecting isoleucine catabolism (OMIM 610006).

2. Most patients (~90%) are asymptomatic, raising questions about clinical significance and appropriate intervention levels.

3. Strong founder effects exist in the Hmong (c.1165A>G) and Somali/Eritrean (c.303+3A>G) populations, accounting for the majority of known cases.

4. Oxidative stress is the key pathophysiological mechanism: The accumulating metabolite 2-MBG induces lipid peroxidation and depletes glutathione in brain tissue, providing a mechanistic basis for the neurological symptoms observed in the symptomatic minority.

5. Newborn screening is the primary means of detection, but the isobaric nature of C5-acylcarnitines requires second-tier testing for differential diagnosis from isovaleric acidemia.

6. Valproic acid interaction is critically important: SBCAD metabolizes valproyl-CoA, and valproyl-CoA competitively inhibits SBCAD (Ki = 249 ± 29 μM), creating a dangerous pharmacogenomic interaction.

7. Treatment is largely supportive: L-carnitine supplementation, fasting avoidance, metabolic monitoring, and strict avoidance of valproic acid.

Ontology Term Summary

Limitations and Knowledge Gaps

1. Incomplete penetrance is unexplained: Why ~90% of individuals with biallelic ACADSB mutations remain asymptomatic is unknown. Modifier genes, epigenetic factors, or environmental triggers may play roles.

2. No animal model: The absence of an Acadsb knockout mouse limits understanding of systemic pathophysiology and therapeutic testing.

3. Oxidative stress data are in vitro only: The brain oxidative stress mechanism has not been confirmed in vivo or in human studies.

4. Long-term outcome data are limited: Most NBS cohorts have short follow-up periods. Adult outcomes of NBS-detected individuals are unknown.

5. Genotype–phenotype correlation is poor: The same c.1165A>G Hmong founder mutation produces both symptomatic and asymptomatic individuals.

6. Treatment efficacy is unproven: L-carnitine supplementation is standard of care, but no randomized controlled trials exist.

7. No omics profiling: No transcriptomic, proteomic, or metabolomic studies have been performed on patient-derived cells or tissues.

8. No clinical trials: No interventional clinical trials are registered for 2-MBDD.

9. Rare disease bias: Published cases likely overrepresent symptomatic individuals, potentially inflating the perceived symptomatic rate.

Proposed Follow-up Experiments and Actions

High Priority

1. Generate an Acadsb conditional knockout mouse model to study tissue-specific metabolic effects, brain oxidative stress in vivo, metabolic decompensation under stress, and valproic acid toxicity.

2. Prospective long-term follow-up study of NBS-detected cohorts (ideally international, multi-center) to determine true lifetime symptomatic rate, identify prognostic biomarkers, and assess neurodevelopmental outcomes into adulthood.

3. Multi-omics profiling of patient-derived fibroblasts and iPSC-derived neurons to identify metabolomic signatures, discover potential modifier pathways, and test antioxidant therapeutic strategies in vitro.

Medium Priority

1. Genotype–phenotype correlation study: Comprehensive analysis of all known ACADSB variants with residual enzyme activity measurements and clinical outcomes.

2. Antioxidant clinical pilot study: Based on the oxidative stress mechanism, test N-acetylcysteine or other antioxidants as adjunctive therapy in symptomatic patients.

3. Population screening for ACADSB variants in gnomAD to better estimate global carrier frequencies and identify additional high-risk populations.

Lower Priority

1. R-pathway enzyme identification: Identify the enzyme(s) responsible for R-2-methylbutyryl-CoA dehydrogenation, which could be a therapeutic target to enhance the protective shunt pathway.

2. Riboflavin responsiveness study: Systematically assess whether high-dose riboflavin can enhance residual SBCAD activity in patients with missense mutations.

3. Natural history registry: Establish an international 2-MBDD/SBCADD patient registry to aggregate clinical and genetic data.

Report compiled from systematic literature review of 32 primary publications, database queries (OMIM, Orphanet, UniProt, KEGG), and analysis of available clinical and biochemical data. All citations are linked to PubMed identifiers for verification. Report generated May 2026.